News from Panmira, BIA and Weiler Labeling Systems – People on the move
Panmira has named Hari Kumar as its new CEO.
Kumar steps up to the role after serving as chief business officer for Amira, where he headed the firm’s sale of its fibrosis program to Bristol-Myers Squibb.
In his new position, Kumar will lead efforts on Panmira's inflammation portfolio, which features a best-in-class CRTH2 program.
The BioIndustry Association (BIA) has drafted in four new members to its board of directors; Janis Clayton, Keith Martin, Diana Sternfeld and Ian Tomlinson.
Clayton – the general manager and VP of Shire Human Genetic Therapies – was previously MDatCephalon, as well as business unit director for Serono.
Apitope CEO Keith Martin has published over 150 papers, reviews & abstracts and is an inventor on 10 patents.
Sternfeld is partner at Rouse Legal. She is one of the UK’s best known international patent litigators, with a specialism in the life sciences industry.
And Tomlinson, the senior VP and head of biopharmaceuticals R&D and worldwide business development at GlaxoSmithKline, has also recently joined the board at Stevenage Bioscience Catalyst (SBC).
The new Board members will serve from 1 January 2012.
Weiler Labeling Systems (WLS) has appointed Jonathan Guy as VP, sales and marketing.
In the newly created position, Guy will be responsible for the management the sales team, marketing strategy including print, online and trade show activities, new product strategy, geographic expansion and partnership assessment.
Ted Geiselman, president of WLS, said: "Jon's significant sales and marketing experience and capability are exactly what we currently need at WLS as we continue our efforts to enhance our products, address the competition and better meet our customer's needs. He will help define the path we take in the future to grow our overall business."
Former Eli Lilly president Scott Canute will join the board of directors at Oncobiologics.
After 30 years with Lilly, Canute also had a brief stint as president of global manufacturing and corporate operations for Genzyme, where he led a major turnaround effort.
In his new role he will help to guide the start-up company as it finds its feet in the industry.
He said: "Oncobiologics has assembled an impressive team of industry leaders, and already has developed a promising pipeline.
“Although the company is a start-up, it has the horsepower of a much more established organization. I look forward to helping steer the company through this exciting stage."
EBR Systems has hired Allan Will as president and CEO.
Will retains his prior position as chairman of the company's board of directors, whilst taking the helm from company co-founder and CEO Rick Riley.
Riley will remain with the company as chief operating officer and director.
Will said: “I am very excited to assume this increased role at EBR. The Company’s wireless pacing technology promises to be the next major advance in cardiac rhythm management.
“Ultimately, our wireless capability can replace all pacing leads, increasing efficacy and decreasing complications in bradycardia therapy as well as heart failure.”
